Aspergillosis is a group of diseases caused by molds in the genus Aspergillus, and it ranges from mild allergic reactions to life-threatening invasive infections depending on a person’s immune status and the amount of fungus inhaled. The most common culprit is Aspergillus fumigatus, a species so widespread in soil, decaying vegetation, and indoor dust that virtually everyone breathes in its microscopic spores daily. For healthy people this is a non-event. But for those with weakened immune systems or certain lung conditions, the same spores can take hold and cause serious harm.
Where Aspergillus Lives and How You Encounter It
The genus Aspergillus includes a few hundred species found across a wide range of climates and environments, from tropical forests to temperature-controlled buildings. They thrive on organic matter: compost heaps, fallen leaves, stored grain, even household dust and damp wallboard. The fungus reproduces by releasing enormous numbers of tiny spores called conidia into the air. These spores are small enough to travel deep into the lungs when inhaled.
Among the disease-causing species, A. fumigatus dominates, followed by A. flavus, A. niger, A. terreus, and A. nidulans.{1Europe PMC. Aspergillus fumigatus and related species} Indoor environments can harbor meaningful concentrations of these molds, particularly in damp or poorly ventilated buildings, making occupational and public-health exposure a real concern in some settings.{2PubMed Central. Aspergillus species in indoor environments and their possible occupational and public health hazards} You cannot realistically avoid Aspergillus spores altogether. The question is not whether you are exposed, but whether your body can handle what it encounters.
Why Most People Never Get Sick
A healthy immune system deals with inhaled Aspergillus spores efficiently and silently. Immune cells in the lungs, particularly macrophages and neutrophils, recognize and destroy the spores before they can germinate into the branching filaments that cause tissue damage. Research has shown that the defense network goes well beyond those first-responder cells: circulating monocytes, dendritic cells, and natural killer cells all contribute to an effective response against A. fumigatus.{3PubMed Central. Immune responses against Aspergillus fumigatus: what have we learned?}
The fungus, for its part, has evolved ways to dodge the immune system. One of its key weapons is gliotoxin, a toxin that can suppress immune-cell function and promote colonization, particularly in people with cystic fibrosis. In that setting, gliotoxin reduces the activity of the vitamin D receptor, shifting the airway’s immune balance in a direction that favors the fungus.{4PubMed. Immunoevasive Aspergillus virulence factors} This tug-of-war between fungal evasion strategies and host defenses is what determines whether disease develops. When the immune system is intact, it wins decisively. When it is compromised by medication, illness, or genetics, the fungus gets an opening.
Allergic Bronchopulmonary Aspergillosis
Not all aspergillosis involves the fungus physically invading tissue. In allergic bronchopulmonary aspergillosis, or ABPA, the problem is an overblown immune reaction to Aspergillus growing in the airways of people who already have asthma or cystic fibrosis. The immune system mounts an exaggerated inflammatory response marked by very high levels of certain antibodies, elevated blood eosinophil counts, and characteristic lung imaging abnormalities including bronchiectasis and mucus plugging.{5Journal of Inflammation Research. Asthma and Allergic Bronchopulmonary Aspergillosis: Understanding, Insights, and State-of-the-Art}
The hallmark symptoms of ABPA include asthma that stubbornly resists standard treatment, recurring lung opacities that come and go on chest imaging, and progressive bronchiectasis if the condition goes untreated.{6PubMed Central. Allergic bronchopulmonary aspergillosis} If you have asthma and your symptoms keep worsening despite good treatment, ABPA is one of the diagnoses a pulmonologist should consider. Catching it early matters because the progressive bronchiectasis can cause permanent lung damage, while early treatment with corticosteroids and antifungals can keep the condition under control.
Aspergilloma and Chronic Pulmonary Forms
An aspergilloma, sometimes called a fungus ball, forms when Aspergillus colonizes an existing cavity in the lung. The cavity might be a scar from old tuberculosis, a healed abscess, or a cyst from another lung disease. The fungus grows within this space, accumulating into a dense mass of fungal filaments, mucus, and debris.{7PubMed Central. Clinical manifestations and treatment outcomes of pulmonary aspergilloma} In parts of the world where tuberculosis is common, healed TB cavities are a particularly frequent site for aspergilloma to develop.{8PubMed Central. Surgical treatment of pulmonary aspergillosis: A single center experience}
Many aspergillomas sit quietly in the lung and cause no symptoms at all, discovered incidentally on a chest X-ray taken for another reason. When they do cause problems, the most common and most alarming symptom is coughing up blood, which can range from streaks to massive hemorrhage. This bleeding happens because the fungus erodes into blood vessels lining the cavity wall. Treatment with antifungal drugs alone has limited success for chronic forms. A multicenter trial of voriconazole for chronic pulmonary aspergillosis reported a six-month overall response rate of about 32%, with better results for necrotizing disease than for cavitary disease.{9Europe PMC. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial} When bleeding is severe or recurrent, surgery to remove the affected portion of lung is often the definitive treatment.
Surgery for Aspergilloma
Surgical removal is considered the most reliable way to eliminate an aspergilloma that causes significant symptoms. The most common reason patients end up in the operating room is hemoptysis (coughing up blood), which drives the decision in the vast majority of cases. In one retrospective series, hemoptysis was the surgical indication in over 96% of patients, and the procedures performed were overwhelmingly lobectomies, with a postoperative mortality rate under 2%.{10PubMed. Clinical profile and surgical outcome for pulmonary aspergilloma: nine year retrospective observational study in a tertiary care hospital}
That said, operating on a lung riddled with chronic inflammatory changes is no small undertaking. Complication rates in the range of 20–25% are typical, mostly related to bleeding, air leaks, and wound infections. For that reason, surgical treatment is generally reserved for patients with significant symptoms in whom lobectomy is feasible, rather than used preemptively on asymptomatic fungus balls. Long-term outcomes after surgery are encouraging, with symptom relief in most patients and a very low rate of disease recurrence.{11PubMed Central. Surgical treatment for pulmonary aspergilloma – early and long-term results}
Invasive Aspergillosis
Invasive aspergillosis is the most dangerous form of the disease. Here, the fungus actively invades lung tissue and can spread through the bloodstream to the brain, heart, kidneys, and other organs. It occurs almost exclusively in people with severely weakened immune systems: patients on chemotherapy, organ transplant recipients taking immunosuppressive drugs, or people with prolonged very low white blood cell counts.
The clinical picture depends on the type of immune deficiency. Patients with very low neutrophil counts tend to develop nodules and dense consolidation in the lungs, often with the CT halo sign, a ring of ground-glass opacity around a nodule that strongly suggests the fungus is invading blood vessels.{12PubMed Central. The CT halo sign in invasive aspergillosis} Organ transplant recipients with invasive aspergillosis, by contrast, are more likely to present with patchy consolidation and ground-glass changes rather than nodules, and they are less likely to have a fever, making the diagnosis easier to miss in that group.{13PubMed. Clinical and radiological features of invasive pulmonary aspergillosis in transplant recipients and neutropenic patients}
When the fungus reaches the central nervous system, outcomes are especially grim. Brain involvement can occur either by blood-borne spread in people with suppressed immunity or by direct extension from the sinuses or from traumatic inoculation in otherwise healthy individuals.{14PubMed Central. Central Nervous System Infections Due to Aspergillus and Other Hyaline Molds} While the lungs are by far the most common site of Aspergillus infection, central nervous system involvement remains one of the most feared complications.{15PubMed Central. A Complex Case of Aspergillus Infection of the Brain and Its Future Medical Implications}
The Diagnosis Challenge
Diagnosing aspergillosis, particularly the invasive form, is notoriously difficult. Cultures take time and often come back negative even when the fungus is present. Clinicians have therefore turned to blood-based biomarkers that detect molecules shed by growing Aspergillus.
The two main blood tests are the galactomannan (GM) assay and the beta-D-glucan (BG) assay. Neither is perfect on its own. A meta-analysis of their performance found that serum galactomannan catches about half of invasive aspergillosis cases (pooled sensitivity around 53%) but is very good at ruling out the disease when negative (specificity about 94%). Beta-D-glucan is more sensitive (about 72%) but less specific (about 82%). Using both tests together raises sensitivity to roughly 84%, which is a meaningful improvement over either alone.{16PubMed Central. Diagnostic performance of serum galactomannan and β-D-glucan for invasive aspergillosis in suspected patients: A meta-analysis}
Testing the galactomannan in lung-washing fluid rather than blood provides much better sensitivity. A Cochrane review found that bronchoalveolar lavage galactomannan at the standard cutoff had a sensitivity of about 88% and specificity of 81% in patients with impaired immune systems.{17Cochrane Database of Systematic Reviews. Measuring galactomannan in lung‐washing fluid to diagnose invasive aspergillosis in patients with an impaired immune system} The practical takeaway is that when invasive aspergillosis is suspected, getting fluid directly from the lungs through bronchoscopy substantially improves the odds of nailing the diagnosis compared to blood tests alone.
Imaging adds another layer. The CT halo sign, when present in a patient with a severely compromised immune system, is strongly suggestive of invasive aspergillosis, while a different pattern called the reversed halo sign points more toward another fungal infection, mucormycosis.{18Clinical Infectious Diseases. The Diagnostic Value of Halo and Reversed Halo Signs for Invasive Mold Infections in Compromised Hosts} Recognizing these patterns early can push clinicians toward the right treatment faster.
Aspergillosis After Severe Viral Pneumonia
One of the more unsettling developments in recent years has been the recognition that severe influenza and COVID-19 can open the door to invasive aspergillosis even in patients who were not traditionally considered high-risk. Influenza-associated pulmonary aspergillosis (IAPA) and COVID-19-associated pulmonary aspergillosis (CAPA) have been diagnosed in roughly 10–20% of ICU patients with severe viral pneumonia when clinicians actively look for the infection using appropriate diagnostic tools.{19The Lancet Respiratory Medicine. Mechanistic and clinical aspects of influenza-associated pulmonary aspergillosis and COVID-19-associated pulmonary aspergillosis}
The outcomes for these patients are poor even with antifungal treatment. Fatality rates often exceed 50%.{20The Lancet Respiratory Medicine. Influenza-associated pulmonary aspergillosis and COVID-19-associated pulmonary aspergillosis: a review} Part of the problem is that diagnosing aspergillosis in a patient already critically ill with viral pneumonia is genuinely hard: the symptoms and imaging findings overlap substantially, and clinicians may not think to look for a fungal co-infection unless they are aware this entity exists. Awareness has improved considerably since the COVID pandemic forced the issue, and many ICUs now incorporate fungal biomarker testing into their protocols for severely ill patients on ventilators.
Antifungal Resistance and Why It Matters
The first-line drugs for invasive aspergillosis are azole antifungals, particularly voriconazole and isavuconazole. When these stop working because the fungus has developed resistance, treatment options shrink and mortality climbs. Azole-resistant A. fumigatus has been found on every continent, and one much-debated question is whether agricultural use of azole-based fungicides on crops is driving the emergence of resistance in clinical isolates.
The concern is straightforward: the azoles sprayed on tulip fields and wheat crops are chemically similar to the azoles used in medicine. If A. fumigatus living in agricultural soil develops resistance by surviving crop fungicide exposure, those resistant spores could later infect a human patient. A study examining this directly found that the overall resistance rate among agricultural isolates was low, about 1–3%, and that there was no strong evidence that azole use on crops was a significant driver of resistance in their study context. However, the researchers did observe a subtle but consistent decrease in azole susceptibility among isolates collected after the growing season and fungicide exposure.{21PubMed Central. Effects of Agricultural Fungicide Use on Aspergillus fumigatus Abundance, Antifungal Susceptibility, and Population Structure} Other research groups, particularly in the Netherlands where azole-resistant aspergillosis has been a problem for longer, have found stronger links. The picture remains incomplete, but the possibility that agricultural practices could erode the effectiveness of life-saving medical drugs has reshaped how public health experts think about fungicide regulation.
Protecting Vulnerable Patients in Hospitals
Since Aspergillus spores are airborne, hospital environments require careful engineering to protect patients whose immune systems cannot handle even normal ambient exposure. Construction and renovation projects are particularly dangerous moments, because demolition stirs up enormous quantities of dust and fungal spores. Performing infection-control risk assessments before and during construction is considered essential to prevent healthcare-associated fungal outbreaks.{22Clinical Infectious Diseases. Review of Fungal Outbreaks and Infection Prevention in Healthcare Settings During Construction and Renovation}
High-efficiency particulate air (HEPA) filtration is the primary engineering control. In wards housing patients with blood cancers and other high-risk conditions, installing portable HEPA filters has been shown to cut the incidence of invasive aspergillosis roughly in half. One study found the rate dropped from about 35 to about 18 cases per 100,000 patient-days after HEPA filters were placed, while wards without the filters saw no such change.{23American Journal of Infection Control. Impact of portable high-efficiency particulate air filters on the incidence of invasive aspergillosis in a tertiary-care hospital} Purpose-built positive-pressure rooms with built-in HEPA filtration offer even stronger protection. The evidence that HEPA filtration helps is consistent, though researchers continue to study exactly how much of the benefit comes from filtration versus other concurrent infection-control measures.{24PubMed Central. What’s New in Prevention of Invasive Fungal Diseases during Hospital Construction and Renovation Work: An Overview}
Emerging Therapeutic Approaches
Because antifungal drugs alone often cannot eradicate invasive aspergillosis, particularly in patients whose immune systems remain suppressed, researchers are exploring immune-based treatments that could be used alongside conventional antifungals. These include cytokine therapy (giving patients immune-signaling molecules to boost their fungal defenses), monoclonal antibodies targeting Aspergillus components, and cellular immunotherapy where immune cells are primed to fight the fungus and then infused into the patient.{25PubMed. Immunotherapeutic approaches for fungal infections} None of these has become standard treatment yet, but the direction of research reflects a growing recognition that drugs and the immune system need to work as a team, especially for the sickest patients.
Aspergillosis in Animals
Aspergillosis is not just a human problem. It is relatively uncommon in mammals overall, but dogs, horses, cows, and dolphins are among the susceptible species. In birds, the situation is dramatically different: aspergillosis is a major cause of death, particularly in captive and wild birds kept in stressful or crowded conditions such as aviaries, rehabilitation centers, and poultry farms.{26PubMed. Aspergillosis in mammals and birds: impact on veterinary medicine} Birds’ respiratory anatomy, with air sacs extending deep into the body, gives inhaled spores access to a much larger surface area than in mammalian lungs, making birds inherently more vulnerable.
From a public health perspective, birds may also play a role in the ecology of drug-resistant Aspergillus. Because birds encounter both environmental and agricultural sources of Aspergillus, and because captive birds are sometimes treated with azole antifungals, they represent another potential reservoir where resistance can develop and spread.{27PubMed Central. Aspergillosis, Avian Species and the One Health Perspective: The Possible Importance of Birds in Azole Resistance} The connections between human medicine, veterinary medicine, and agricultural practice in shaping fungal resistance are a growing area of research under the “One Health” framework.
The Other Side of Aspergillus
It would be misleading to leave the impression that Aspergillus is nothing but a threat. Several species have been workhorses of industrial biotechnology for decades. Aspergillus niger is the world’s primary producer of citric acid, the tart compound in soft drinks and countless processed foods. Aspergillus oryzae has been used in East Asian food production for centuries, playing essential roles in making soy sauce, sake, and miso. Both species, along with Trichoderma reesei, have long histories of safe use in enzyme production for industrial applications.{28PubMed Central. Safety of the fungal workhorses of industrial biotechnology: update on the mycotoxin and secondary metabolite potential of Aspergillus niger, Aspergillus oryzae, and Trichoderma reesei} The genus was named in 1729 by the Italian biologist Pier Antonio Micheli, who thought the spore-bearing structures looked like an aspergillum, the brush used to sprinkle holy water in Catholic liturgy.{29Europe PMC. Etymologia: Aspergillus} That a group of organisms named after a church implement can simultaneously ferment your soy sauce and threaten the life of a transplant patient captures the biological range of this remarkable genus.